Close

Press Releases

Oncodesign and Ipsen enter into a research collaboration for the development of new therapeutic agents against the LRRK2 Parkinson’s disease target

Oncodesign, a Drug Discovery company and Oncology pharmacology service provider, and Ipsen (Euronext: IPN,ย ADR: IPSEY), a global specialty-driven pharmaceutical company, announced today that the two companies haveย entered into a research collaboration to discover and develop innovative LRRK2 kinase...

World Pharma Today: Goose Bags Strides Arcolab, Indoco Remedies and Macleods โ€˜Track & Traceโ€™ Deals

Goose Leads Track & Trace Solutions Pack; New Customer wins gives booster to market confidenceHyderabad, India, Hyderabad based Goose ย (www.goose.co.in) indigenously developed B2B Track and Trace solution Tracker aimed at helping pharma companies detect counterfeit drugs and protect their...

Fluxion Biosciences Launches the F1 Giga-Ohm Seal Plates for the IonFlux System

Fluxion Biosciences announced that it has introduced F1 giga-ohm seal plates for the IonFlux automated patch clamp system. The newly launched F1 plates complement Fluxionโ€™s existing 20-cell ensemble recording plates and are fully compatible with all IonFlux systems. Users...

Cytheris announces interim results from ECLIPSE II Hepatitis C multicenter study of IL-7 in chronically infected genotype one and four nonresponders to standard of...

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its ECLIPSE II Phase I/IIa study indicate that treatment with four weeks...

FDA Approves ERBITUX for First-Line Recurrent Locoregional or Metastatic Head and Neck Cancer in Combination with Platinum-based Chemotherapy with 5-Fluorouracil

Eli Lilly and Company and Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) has approved ERBITUXยฎ (cetuximab), in combination with platinum-based chemotherapy with 5-fluorouracil (CT), for the first-line treatment of recurrent locoregional or metastatic squamous...

Trophos initiates phase II proof of concept study for novel cardioprotective compound, TRO40303, in acute myocardial infarction

Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announces today that the first patient has been treated in a phase II proof-of-concept study...

Hybrigenicsโ€™ specific inhibitor of Ubiquitin-Specific Protease 7 (USP7) is cytotoxic for chronic lymphocytic leukaemia (CLL) cells in vitro

Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments against proliferative diseases, today announces the presentation by Professor Tatjana Stankovic, from the University of Birmingham (UK) School...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate ยป